US FDA’s final guidance spells out how to use standard dissolution methods for new drug applications and abbreviated new drug applications for highly soluble immediate-release solid oral dosage forms. FDA said that the guidance should also facilitate the agency’s review of the data submitted in applications.
The guidance also describes when a standard release test may be used in lieu of extensive method development and acceptance...